Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

531 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Initiating or Switching to Insulin Degludec/Insulin Aspart in Adults with Type 2 Diabetes: A Real-World, Prospective, Non-interventional Study Across Six Countries.
Fulcher GR, Akhtar S, Al-Jaser SJ, Medina J, Mohamed M, Nicodemus NA Jr, Olsen AH, Singh KP, Kok A. Fulcher GR, et al. Among authors: kok a. Adv Ther. 2022 Aug;39(8):3735-3748. doi: 10.1007/s12325-022-02212-3. Epub 2022 Jun 25. Adv Ther. 2022. PMID: 35752730 Free PMC article. Clinical Trial.
Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial.
Aroda VR, González-Galvez G, Grøn R, Halladin N, Haluzík M, Jermendy G, Kok A, Őrsy P, Sabbah M, Sesti G, Silver R. Aroda VR, et al. Among authors: kok a. Lancet Diabetes Endocrinol. 2019 Aug;7(8):596-605. doi: 10.1016/S2213-8587(19)30184-6. Epub 2019 Jun 9. Lancet Diabetes Endocrinol. 2019. PMID: 31189519 Clinical Trial.
ARISE-a prospective, non-interventional, single-arm study assessing clinical parameters associated with the use of insulin degludec/insulin aspart in patients with type 2 diabetes in real-world settings: rationale and design.
Fulcher GR, Jarlov H, Piltoft JS, Singh KP, Liu L, Mohamed M, Nicodemus NA Jr, Al-Jaser SJ, Kok A. Fulcher GR, et al. Among authors: kok a. Endocrine. 2021 Dec;74(3):530-537. doi: 10.1007/s12020-021-02887-8. Epub 2021 Oct 12. Endocrine. 2021. PMID: 34637072 Free PMC article.
Correction: ARISE-a prospective, non-interventional, single-arm study assessing clinical parameters associated with the use of insulin degludec/insulin aspart in patients with type 2 diabetes in realworld settings: rationale and design.
Fulcher GR, Jarlov H, Piltoft JS, Singh KP, Liu L, Mohamed M, Nicodemus NA Jr, Al-Jaser SJ, Kok A. Fulcher GR, et al. Among authors: kok a. Endocrine. 2022 Mar;75(3):964. doi: 10.1007/s12020-021-02956-y. Endocrine. 2022. PMID: 34919203 Free PMC article. No abstract available.
Correction to: Initiating or Switching to Insulin Degludec/Insulin Aspart in Adults with Type 2 Diabetes: A Real-World, Prospective, Non-interventional Study Across Six Countries.
Fulcher GR, Akhtar S, Al-Jaser SJ, Medina J, Mohamed M, Nicodemus NA Jr, Olsen AH, Singh KP, Kok A. Fulcher GR, et al. Among authors: kok a. Adv Ther. 2023 Jan;40(1):389-390. doi: 10.1007/s12325-022-02349-1. Adv Ther. 2023. PMID: 36315342 Free PMC article. No abstract available.
Characteristics and Treatment Patterns of Patients with Type 2 Diabetes Mellitus in the Middle East and Africa Cohort of the DISCOVER Study Program: a Prospective Study.
Al-Rubeaan K, Alsayed M, Ben-Nakhi A, Bayram F, Echtay A, Hadaoui A, Hafidh K, Kennedy K, Kok A, Malek R, Rajadhyaksha V, Arnold SV. Al-Rubeaan K, et al. Among authors: kok a. Diabetes Ther. 2022 Jul;13(7):1339-1352. doi: 10.1007/s13300-022-01272-6. Epub 2022 Jun 11. Diabetes Ther. 2022. PMID: 35689732 Free PMC article.
531 results